GlassScriptPhysician profile
Allison Catherine Mcsherry
NPI 1740974971
$2,362.53
in general payments reported to CMS, 2019-2025
26 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $103 · 2024: $1,216 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $47.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.79 |
| Education | $47.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $259.23 | 2025 | Aurora Ev-Icd Mri Surescan, Micra |
| Pfizer INC. | $199.78 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $195.74 | 2024 | Optimizer |
| Boston Scientific Corporation | $184.63 | 2024 | Watchman Access System, Varithena Administration Pack, Watchman Flx |
| Amgen INC. | $184.55 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.20 | 2024-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $153.93 | 2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $130.38 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.02 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $117.85 | 2023-2025 | Jynarque |
| Novo Nordisk INC | $109.16 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $108.30 | 2023-2024 | Xarelto |
| Calliditas Therapeutics US INC. | $60.21 | 2025 | Tarpeyo |
| Merck Sharp & Dohme LLC | $53.59 | 2024-2025 | Winrevair |
| Lilly USA, LLC | $47.80 | 2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $47.74 | 2024 | Rayaldee |
| Travere Therapeutics, INC. | $43.58 | 2023-2024 | |
| Esperion Therapeutics, INC. | $28.93 | 2024-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.80 | 2025 | Lifevest |
| Abiomed | $21.60 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.69 | 2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $18.98 | 2025 | Farxiga |
| Ardelyx, INC. | $18.65 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Alexion Pharmaceuticals, INC. | $14.93 | 2025 | Ultomiris |
| Baxter Healthcare | $14.72 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Mcsherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.